Drug Trial Radar · NCT04868604
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Aug 11, 2021
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Clarity Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Conditions
- Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-bisPSMADrug
64Cu-SAR-bisPSMA
67Cu-SAR-bisPSMADrug
67Cu-SAR-bisPSMA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biodistribution of 64Cu-SAR-bisPSMATime frame: 48 hours
- Dosimetry of 64Cu-SAR-bisPSMATime frame: 48 hours
- Modelling of 67Cu-SAR-bisPSMA dosimetry utilizing the 64Cu-SAR-bisPSMA PET/CT scansTime frame: 48 hours
- Maximum Tolerated Dose (MTD) or Maximum Feasible Dose of a single dose of 67Cu-SAR-bisPSMATime frame: 8 weeks
- Recommended dose of two doses of 67Cu-SAR-bisPSMATime frame: 14 weeks
- Efficacy of 67Cu-SAR-bisPSMA in terms of Prostate specific Antigen (PSA) responseTime frame: Up to 5 years
- Efficacy of 67Cu-SAR-bisPSMA in terms of radiographic responseTime frame: Up to 5 years
- Incidence of 67Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 5 years
- Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in Vital SignsTime frame: Up to 1 year
- Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in electrocardiogram (ECG) parametersTime frame: Up to 24 weeks
- Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in laboratory resultsTime frame: Up to 22 weeks
- Incidence of 64Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 5 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Stanford Cancer Institute
Stanford, California · Recruiting
East Jefferson General Hospital
River Ridge, Louisiana · Recruiting
BAMF Health
Grand Rapids, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University School of Medicine at Barnes-Jewish Hospital
St Louis, Missouri · Recruiting
XCancer
Omaha, Nebraska · Recruiting
Weill Cornell Medicine at New York-Presbyterian
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.